The introduction of oral GLP-1 weight-loss medicines in the UAE is expanding treatment choices for obesity and diabetes, especially for patients who struggle with needle phobia. The approval of Foundayo, a once-daily oral GLP-1 for chronic weight management, along with the availability of oral semaglutide under Rybelsus for adults with type 2 diabetes, is changing how doctors discuss metabolic health and long-term weight control.
For many patients, injections have long been a barrier to starting treatment. Needle phobia is not just discomfort but can lead to missed appointments, delayed therapy, or abandoning prescriptions altogether. In this context, oral GLP-1 medicines offer a more accessible first step, allowing patients to begin treatment with a daily tablet rather than an injection.
Gold 101.3FM UAE’s No.1 radio station continues to bring the latest health and lifestyle updates for listeners across the UAE.
However, doctors caution that oral options are not necessarily simpler. Weekly injectable GLP-1 treatments require only one dose per week, while oral tablets demand strict daily adherence. Some oral semaglutide formulations must also be taken on an empty stomach with limited water, followed by a waiting period before food, coffee, or other medications—making morning routines more complex, especially in busy lifestyles.
Foundayo may reduce some of these limitations as a once-daily oral option with fewer intake restrictions, but consistency remains essential. Missing doses in daily tablets can reduce effectiveness, sometimes making injectables easier for certain patients despite initial fear.
Experts emphasize that the choice between pills and injections should depend on lifestyle fit rather than preference alone. Patients with needle anxiety may benefit from oral therapy, while others with irregular routines or frequent travel may do better on weekly injections.
Doctors also stress that these medications are not quick fixes or cosmetic weight-loss solutions. They work best alongside lifestyle changes such as diet, exercise, sleep management, and regular medical supervision.
The growing availability of GLP-1 options marks a shift toward more personalized obesity care in the UAE—where the “best” treatment is not the newest form, but the one a patient can realistically sustain over time
